Nuveen LLC Acquires New Holdings in SiBone $SIBN

Key Points

• Nuveen LLC has acquired 1,326,100 shares of SiBone, valued at approximately $18.6 million, representing 3.12% of the company's stock.
• Insider trades include CFO Anshul Maheshwari selling 5,005 shares, reducing his ownership by 2.25%, while Director Jeffrey W. Dunn sold 3,377 shares, decreasing his ownership by 16.29%.
• SiBone's stock price recently opened at $15.49, with a twelve-month range of $11.70 to $20.05, and is currently rated as a "Buy" by several firms with an average target price of $23.67.

Nuveen LLC bought a new stake in shares of SiBone (NASDAQ:SIBN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,326,100 shares of the company's stock, valued at approximately $18,605,000. Nuveen LLC owned 3.12% of SiBone at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd purchased a new stake in shares of SiBone in the first quarter worth about $34,000. Virtus Fund Advisers LLC purchased a new position in SiBone during the fourth quarter worth $40,000. GAMMA Investing LLC boosted its position in shares of SiBone by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after buying an additional 3,867 shares during the period. Johnson Investment Counsel Inc. purchased a new stake in shares of SiBone in the first quarter worth approximately $148,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of SiBone during the first quarter worth $162,000. Institutional investors own 98.11% of the company's stock.

SiBone Price Performance

SIBN stock traded up $0.75 during midday trading on Friday, reaching $16.39. The stock had a trading volume of 333,628 shares, compared to its average volume of 509,321. SiBone has a 52-week low of $11.70 and a 52-week high of $20.05. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. The company's fifty day simple moving average is $17.06 and its 200 day simple moving average is $16.54. The company has a market cap of $707.06 million, a price-to-earnings ratio of -29.27 and a beta of 0.91.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. The business had revenue of $48.63 million during the quarter, compared to analysts' expectations of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the stock an "overweight" rating in a report on Monday, August 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SiBone in a research report on Tuesday, May 6th. Truist Financial lifted their target price on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Finally, Wall Street Zen lowered shares of SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, SiBone has a consensus rating of "Buy" and a consensus price target of $23.67.

Insiders Place Their Bets

In other news, Director John Gordon Freund sold 12,132 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $15.99, for a total transaction of $193,990.68. Following the transaction, the director owned 91,767 shares of the company's stock, valued at approximately $1,467,354.33. The trade was a 11.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Laura Francis sold 11,343 shares of SiBone stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.60, for a total transaction of $176,950.80. Following the transaction, the chief executive officer directly owned 419,704 shares in the company, valued at $6,547,382.40. This trade represents a 2.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,967 shares of company stock worth $829,469. 4.00% of the stock is currently owned by company insiders.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.